What Is Orforglipron? Lilly's Oral GLP-1 Weight Loss Pill
Orforglipron (development code: LY3502970) is an investigational oral GLP-1 receptor agonist developed by Eli Lilly. Unlike every other GLP-1 drug on the market — which are injectable peptides — orforglipron is a small molecule that can be taken as a once-daily pill with no food or water restrictions.
In the Phase 3 ATTAIN-1 trial, orforglipron produced 12.4% body weight loss at 72 weeks. In a head-to-head diabetes trial (ACHIEVE-3), it outperformed oral semaglutide on both HbA1c reduction and weight loss. Lilly has filed orforglipron for approval in over 40 countries, with a US FDA decision for obesity expected in Q2 2026.
Orforglipron does not have a brand name yet. It is part of Eli Lilly's broader weight loss portfolio alongside tirzepatide (Mounjaro/Zepbound) and retatrutide.
How Orforglipron Works
A Non-Peptide GLP-1 Agonist
Every currently approved GLP-1 drug — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda) — is a peptide. Peptides are chains of amino acids that get destroyed by stomach acid and digestive enzymes, which is why they require injection.
Orforglipron solves this by being a non-peptide small molecule. It is chemically synthesized (not biologically derived) and is stable in the gastrointestinal tract. This means:
- No injection needed — taken as a once-daily oral pill
- No fasting required — unlike oral semaglutide (Rybelsus), which requires 30 minutes of fasting with only a sip of water
- No food or water restrictions — can be taken at any time of day with or without meals
Biased Agonism
According to Lilly Medical, orforglipron binds to the same GLP-1 receptor as native GLP-1 but exhibits biased agonism — it favors G-protein signaling (specifically cAMP accumulation, which drives the therapeutic effects) over beta-arrestin recruitment (which leads to receptor downregulation).
In practical terms: orforglipron activates the receptor's beneficial pathways (appetite suppression, insulin secretion, slowed gastric emptying) while potentially causing less receptor desensitization over time. This is a partial agonist — it does not fully activate the receptor to the same extent as injectable GLP-1 peptides.
What It Does in the Body
Like all GLP-1 receptor agonists, orforglipron:
- Reduces appetite by acting on GLP-1 receptors in the hypothalamus
- Stimulates insulin secretion in response to food (glucose-dependent)
- Suppresses glucagon after meals, preventing excess liver glucose output
- Slows gastric emptying, prolonging fullness after eating
The same receptor, the same downstream effects — just delivered in a pill instead of a needle.
Clinical Trial Data
ATTAIN-1 (Phase 3 — Obesity Without Diabetes)
The ATTAIN-1 trial enrolled 1,686 adults with obesity or overweight (BMI 27+ with comorbidities) without diabetes. Results at 72 weeks:
| Dose | Weight Loss at 72 Weeks | Achieved 10%+ Loss | Achieved 15%+ Loss |
|---|---|---|---|
| Orforglipron 36 mg | -12.4% (27.3 lbs) | 59.6% | 39.6% |
| Orforglipron 12 mg | -9.4% | 44.4% | 25.5% |
| Orforglipron 6 mg | -8.2% | 37.5% | 19.2% |
| Placebo | -2.2% | 12.3% | 5.3% |
All three orforglipron doses met the primary endpoint of superior weight loss vs placebo. The 36 mg dose also showed significant improvements in cardiometabolic risk factors including waist circumference, blood pressure, and fasting glucose. Among 1,127 participants with prediabetes at baseline, orforglipron significantly reduced progression to type 2 diabetes.
ACHIEVE-3 (Phase 3 — Head-to-Head vs Oral Semaglutide in T2D)
The ACHIEVE-3 trial, published in The Lancet in February 2026, was the first head-to-head trial comparing two oral GLP-1 therapies. In 1,698 adults with type 2 diabetes on metformin:
| Oral Semaglutide 7 mg | Oral Semaglutide 14 mg | Orforglipron 12 mg | Orforglipron 36 mg | |
|---|---|---|---|---|
| HbA1c reduction | -1.1% | -1.4% | -1.9% | -2.2% |
| Weight loss | — | -5.3% | — | -9.2% |
| HbA1c under 7% | — | 66.1% | — | 85.4% |
Orforglipron 36 mg produced 73.6% greater relative weight loss than oral semaglutide 14 mg. It also outperformed on every primary and key secondary endpoint.
Important caveat: the oral semaglutide doses used (7 mg and 14 mg) are the diabetes-indication doses. Novo Nordisk's obesity-indication oral semaglutide (the Wegovy pill, approved December 2025) goes up to 25 mg, which would likely narrow the gap.
Phase 2 (Obesity)
An earlier Phase 2 trial in 272 adults without diabetes showed orforglipron 36 mg achieved -9.6% weight loss at 36 weeks — the data that drove Phase 3 development. Results were published in NEJM.
Orforglipron Dosing
Orforglipron is taken once daily as an oral tablet. The Phase 3 program used a titration schedule:
| Week | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 3 mg daily | Starting dose |
| Weeks 3-4 | 6 mg daily | First escalation |
| Weeks 5-6 | 12 mg daily | |
| Weeks 7-8 | 24 mg daily | |
| Week 9+ | 36 mg daily | Target maintenance dose |
No food or water restrictions at any dose. Can be taken at any time of day.
Orforglipron Side Effects
The side effect profile is consistent with the GLP-1 drug class, though GI side effects may be somewhat more pronounced than with oral semaglutide.
From ATTAIN-1
| Side Effect | Orforglipron 36 mg | Placebo |
|---|---|---|
| Nausea | 38.8% | 8.4% |
| Diarrhea | 22.4% | 8.6% |
| Vomiting | 18.5% | 2.5% |
| Constipation | 13.4% | 4.7% |
| Discontinuation due to GI | 5.3-10.3% | — |
Most GI side effects were mild to moderate and concentrated during the titration period. In the ACHIEVE-3 head-to-head trial, nausea and vomiting were more common with orforglipron than with oral semaglutide at the doses tested.
How Orforglipron Compares to Other Drugs
| Orforglipron | Oral Semaglutide (Wegovy Pill) | Tirzepatide (Zepbound) | Retatrutide | |
|---|---|---|---|---|
| Delivery | Once-daily pill | Once-daily pill | Once-weekly injection | Once-weekly injection |
| Molecule type | Non-peptide small molecule | Peptide with absorption enhancer | Peptide | Peptide |
| Receptors | GLP-1 only | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Max weight loss | -12.4% (ATTAIN-1, 72 wks) | -15.3% (OASIS-4, 68 wks, 25 mg) | -22.5% (SURMOUNT-1, 72 wks) | -28.7% (TRIUMPH-4, 68 wks) |
| Food restrictions | None | 30 min fast, sip of water only | None (injectable) | None (injectable) |
| FDA status | Filed, decision Q2 2026 | Approved (Dec 2025) | Approved (2023) | Phase 3 trials |
| Developer | Eli Lilly | Novo Nordisk | Eli Lilly | Eli Lilly |
Orforglipron trades maximum weight loss for maximum convenience. It produces less weight loss than injectable options (roughly half of what retatrutide achieves), but eliminates the injection barrier entirely — no needles, no refrigeration, no injection site reactions.
Orforglipron vs Retatrutide
Both drugs are made by Eli Lilly and will likely coexist in Lilly's product portfolio. They serve fundamentally different roles:
- Orforglipron: An oral pill for people who want convenience and are needle-averse. Best suited as a first-line option in primary care — easy to prescribe, easy to take, moderate weight loss.
- Retatrutide: An injectable triple agonist for people who want maximum weight loss. Best suited for more severe obesity or people who have plateaued on other drugs — 28.7% weight loss from a single molecule.
Lilly's strategy appears to be offering a full spectrum: orforglipron for accessibility, tirzepatide for established efficacy, and retatrutide for maximum weight loss.
For a detailed comparison, see our retatrutide vs orforglipron article.
FDA Approval Timeline and Pricing
- Filed in 40+ countries for both obesity and type 2 diabetes
- US FDA decision for obesity: Expected Q2 2026
- Pricing: Not announced, but oral formulation may allow competitive pricing vs injectable GLP-1 drugs. Analyst estimates project oral GLP-1 pills will be priced lower than injectable counterparts to drive volume.
- Projected sales: Analysts estimate orforglipron could reach $16 billion in annual sales by 2031
Orforglipron does not yet have a brand name.
Frequently Asked Questions
What is orforglipron?
Orforglipron is an investigational oral GLP-1 receptor agonist developed by Eli Lilly. It is a once-daily weight loss and diabetes pill that does not require injections, fasting, or food restrictions. It has been filed for FDA approval in over 40 countries.
How much weight can you lose on orforglipron?
In the Phase 3 ATTAIN-1 trial, the highest dose of orforglipron (36 mg daily) produced an average of 12.4% body weight loss (about 27 pounds) at 72 weeks. About 40% of participants lost 15% or more of their body weight.
Is orforglipron a pill or injection?
Orforglipron is a once-daily oral pill. It is the first non-peptide GLP-1 receptor agonist — a small molecule that survives stomach acid and digestive enzymes, so it can be taken by mouth without any special requirements.
When will orforglipron be FDA approved?
Eli Lilly has filed orforglipron for approval in over 40 countries. The US FDA decision for the obesity indication is expected in Q2 2026. It does not yet have a brand name.
How much will orforglipron cost?
Pricing has not been announced. As an oral small molecule (cheaper to manufacture than injectable peptides), it may be priced competitively. Analyst estimates suggest it will be positioned as a more accessible entry point to GLP-1 therapy than injectables like Zepbound.
What is the difference between orforglipron and tirzepatide?
Orforglipron is a once-daily oral pill that targets only the GLP-1 receptor, producing about 12.4% weight loss. Tirzepatide (Zepbound) is a once-weekly injection that targets both GLP-1 and GIP receptors, producing about 22.5% weight loss. Both are made by Eli Lilly.
What are orforglipron's side effects?
The most common side effects are gastrointestinal: nausea (38.8%), diarrhea (22.4%), vomiting (18.5%), and constipation (13.4%). These are typically mild to moderate and improve after the dose titration period.
Is orforglipron better than Ozempic?
Orforglipron has not been compared head-to-head to injectable semaglutide (Ozempic/Wegovy). It was compared to oral semaglutide (Rybelsus doses) in the ACHIEVE-3 trial and showed superior HbA1c and weight loss results. However, injectable semaglutide at higher doses would likely perform better than the oral doses tested.
What is orforglipron's brand name?
Orforglipron does not have a brand name yet. It is currently identified by its generic name (orforglipron) and development code (LY3502970). A brand name will likely be announced closer to FDA approval.
Sources
- Wharton S, et al. "Orforglipron in adults with obesity." New England Journal of Medicine. 2025. Lilly Press Release
- Rosenstock J, et al. "Orforglipron vs oral semaglutide in type 2 diabetes (ACHIEVE-3)." The Lancet. 2026. Lilly Press Release
- Sloop KW, et al. "The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron." PubMed
- Kansakar U, et al. "Orforglipron: A Comprehensive Review." Int J Mol Sci. 2026;27(3):1409. PMC
- Eli Lilly. "Mechanism of action of orforglipron." Lilly Medical
This article is for informational purposes only and does not constitute medical advice. Orforglipron is an investigational compound. Always consult a healthcare provider before starting any medication.
Sources
- ATTAIN-1 results
Eli Lilly
- Orforglipron comprehensive review
PMC
- Mechanism of action
Lilly Medical
Related reading
Retatrutide vs Orforglipron: Injectable Triple Agonist vs Oral GLP-1
Retatrutide produces 28.7% weight loss via injection. Orforglipron offers 12.4% weight loss as a daily pill. Both are from Eli Lilly.
Retatrutide Pill vs Injection: Is There an Oral Formulation?
Retatrutide is injection-only. Here's why there's no pill, how the injection works, and how oral GLP-1 alternatives compare.
Which GLP-1 Drug Is Best for Weight Loss? (2026 Guide)
Decision framework for choosing the best GLP-1 drug: by max weight loss, CV protection, oral option, diabetes control, or liver fat.